Rigel Pharma (RIGL) Tops Q2 EPS by 12c

Rigel Pharma (NASDAQ: RIGL) reported Q2 EPS of $0.04, $0.12 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $26.89 million versus the consensus estimate of $25.7 million.

For earnings history and earnings-related data on Rigel Pharma (RIGL) click here.

You May Also Be Interested In

• Worthington Steel, Inc. (WS) Misses Q4 EPS by 3c
• Micron Technology (MU) PT Raised to $1,100 at Goldman Sachs
• JPMorgan Starts Accton Technology Corp. (2345:TT) at Overweight